Samrat Pharmachem Share Price | Samrat Pharmachem Stock Screener
SAMRATPH
Pharmaceuticals
Share Price BSE
₹261.35
▲
24.85 (10.51%)
As of July 3, 2026, the Samrat Pharmachem share price (BSE: SAMRATPH) is ₹261.35, up 10.51% from the previous close, with shares trading between ₹243.85 and ₹265.00, and a 52-week range of ₹194.95–₹384.40.
Analyse SAMRATPH stock price history and track historical price performance.
Use the Samrat Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Samrat Pharmachem Market Cap
₹89.97 Cr.
SAMRATPH P/E Ratio (TTM)
-24.38
Samrat Pharmachem P/B Ratio
1.18
EPS (TTM)
₹-10.72
Dividend Yield
-
Debt to Equity
0.13
SAMRATPH 52 Week High
₹384.40
Samrat Pharmachem 52 Week Low
₹194.95
Operating Margin
-1.00%
Profit Margin
-1.03%
SAMRATPH Revenue (TTM)
₹290.00
EBITDA
₹-2.00
Net Income
₹-3.00
Total Assets
₹122.00
Total Equity
₹72.00
Samrat Pharmachem Share Price Chart
Screen Samrat Pharmachem share price with an interactive chart. Analyse SAMRATPH price trends and volatility across different timeframes.
Samrat Pharmachem Company Profile - Fundamental Screener
Screen Samrat Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SAMRATPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE103E01016
Samrat Pharmachem Balance Sheet Screener
Screen SAMRATPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 122 | 122 | 117 | 85 | 57 | 58 | 40 | 41 | 36 | 36 |
| Current Assets | 103 | 103 | 99 | 71 | 47 | 50 | 33 | 33 | 28 | 28 |
| Fixed Assets | 11 | 11 | 11 | 10 | 9 | 7 | 7 | 7 | 7 | 7 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 72 | 65 | 63 | 47 | 30 | 24 | 20 | 19 | 15 | 14 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 69 | 62 | 60 | 44 | 27 | 21 | 17 | 15 | 12 | 11 |
Samrat Pharmachem Income Statement Screener - Profit & Revenue Analysis
Screen Samrat Pharmachem income statement and profit fundamentals.
Analyze SAMRATPH quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Samrat Pharmachem share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 290 | 287 | 283 | 311 | 222 | 180 | 138 | 112 | 93 | 71 | 62 | 48 |
| Expenses | 292 | 276 | 279 | 287 | 198 | 170 | 131 | 108 | 87 | 67 | 61 | 46 |
| EBITDA | -2 | 11 | 4 | 24 | 25 | 9 | 7 | 4 | 6 | 4 | 1 | 2 |
| Operating Profit % | -1.00% | 4.00% | 1.00% | 8.00% | 11.00% | 5.00% | 5.00% | 3.00% | 6.00% | 5.00% | 2.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -3 | 10 | 3 | 23 | 24 | 7 | 6 | 2 | 5 | 3 | 0 | 1 |
| Tax | 0 | 3 | 0 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Net Profit | -3 | 7 | 2 | 17 | 17 | 5 | 4 | 2 | 3 | 2 | 0 | 0 |
| EPS | -10.72 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 | 4.97 | 10.41 | 5.68 | 0.97 | 1.02 |
Samrat Pharmachem Cash Flow Screener - Liquidity Fundamentals
Screen SAMRATPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -10 | 9 | -9 | 18 | 5 | -1 | 2 | 0 | -3 | 0 |
| Investing Activities | 0 | 0 | -3 | -1 | -3 | -2 | 2 | -2 | 1 | -2 |
| Financing Activities | 1 | -11 | 10 | -2 | -2 | 2 | -4 | 2 | 1 | 2 |
| Net Cash Flow | -10 | -2 | -3 | 15 | 0 | -1 | 1 | -1 | -1 | 0 |
Samrat Pharmachem Shareholding Pattern Screener
See Samrat Pharmachem shareholding pattern with promoter, FII, and DII holdings.
Check Samrat Pharmachem promoter holding and ownership changes for SAMRATPH on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 48.64% | 48.64% | 48.95% |
| FII Holding | 3.24% | 3.24% | 0.00% | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% |
| DII Holding | 0.00% | 0.00% | 3.24% | 0.00% | 0.00% | 0.22% | 0.22% | 0.22% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 41.75% | 41.58% | 41.64% | 41.73% | 41.50% | 41.69% | 40.79% | 41.34% |
| Other Holding | 5.93% | 6.09% | 6.04% | 5.95% | 6.17% | 6.22% | 7.11% | 6.25% |
| Shareholder Count | 6,311 | 6,785 | 6,752 | 6,699 | 6,488 | 7,478 | 7,169 | 6,984 |
Samrat Pharmachem Share Dividend Screener - Share Yield Analysis
Check Samrat Pharmachem dividend history with payout and yield data.
View Samrat Pharmachem dividend details including ex-dates and amounts for SAMRATPH stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.51% |
| 2024-March | ₹1.00 | 0.32% |
| 2023-March | ₹1.00 | 0.30% |
| 2022-March | ₹1.00 | 0.28% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Samrat Pharmachem Stock Index Membership
See which indices include Samrat Pharmachem stock.
Check SAMRATPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Samrat Pharmachem Market Events Screener - Corporate Actions
Get Samrat Pharmachem corporate actions including splits, bonuses, and buybacks.
Check Samrat Pharmachem stock events that may affect SAMRATPH share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -20.77% | ||
| Dividend | ₹ 1.00 /share | -18.51% | ||
| Dividend | ₹ 1.00 /share | 162.00% | ||
| Dividend | ₹ 1.00 /share | -18.65% | ||
| Dividend | ₹ 1.00 /share | 76.20% | ||
| Annual General Meeting | NA | 48.09% | ||
| Annual General Meeting | NA | 5.00% | ||
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 17.04% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 24.45% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 1.56% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -14.06% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.67% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 24.89% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -9.48% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -16.31% |
Samrat Pharmachem Competitors Screener - Peer Comparison
Screen SAMRATPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,313 | 39.71 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 180,426 | 69.89 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 162,684 | 75.43 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 118,228 | 30.51 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 115,556 | 22.41 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 113,866 | 27.60 | 35,059 | 3.90% | 4,158 | 67.04 |
| Lupin | 113,741 | 21.14 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,286 | 53.93 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 91,917 | 26.86 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 82,388 | 93.55 | 6,868 | 22.01% | 890 | 71.63 |
Samrat Pharmachem Company Announcements - News Screener
Screen SAMRATPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-02 | Board Meeting Intimation for Notice Of Board Meeting For Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-01 | Closure of Trading Window | - |
| 2026-07-01 | Closure of Trading Window | - |
| 2026-06-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-05-30 | Audited Financial Results For The Quarter And Year Ended 31 March 2026 | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-04-07 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-25 | Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31 2026 | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today | - |
| 2026-02-13 | Un-Audited Financial Results For The Quarter Ended December 31 2025 | - |
| 2026-01-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-29 | Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended December 31 2025 | - |
| 2025-12-29 | Closure of Trading Window | - |
| 2025-12-02 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2025-11-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |